The reduction in price target by B. Riley Securities could lead to a negative short-term impact on Checkpoint Therapeutics' stock price as it suggests a lower valuation than previously estimated. However, the maintenance of a Buy rating indicates the analyst's continued positive outlook on the company's fundamentals, which may mitigate some negative sentiment.